Isopalmitoyl amino acid compounds and preparation methods and applications thereof

Through the amidation reaction of isopalmitoic acid and amino acids, isopalmitoyl amino acid compounds with high water solubility and low irritability were prepared, which solved the irritability and difficulty of degradation of traditional surfactants and met the market's surfactivity of new amino acids. The demand for agents has a wide range of application prospects.

CN114539091BActive Publication Date: 2024-11-05FOSHAN ENANTIOSIC CORP LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210252643.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-03-11
Publication Date
2024-11-05
Estimated Expiration
2042-03-11

AI Technical Summary

Technical Problem

Traditional surfactants have problems such as high irritability, high toxicity, difficulty in degradation and poor compatibility, and the market demand for new amino acid surfactants has increased.

Method used

Develop an isopalmitoyl amino acid compound, and the amino acid surfactant with high water-soluble and low irritation is prepared, suitable for daily chemical and pharmaceutical fields.

Benefits of technology

It has achieved high water solubility and low irritation of amino acid surfactants, and is suitable for daily chemical and pharmaceutical fields, with good application prospects and industrial production potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114539091B_ABST
    Figure CN114539091B_ABST
Patent Text Reader

Abstract

The present invention relates to an isopalmitoyl amino acid compound, the general structural formula of which is shown in formula (I): #imgabs0# wherein Z1 is a C8 alkyl group, Z2 is a C6 alkyl group, R1 is H or an alkyl group, and R2 is H, C 1‑4 Alkyl, benzyl, -L1-X; wherein L1 is C 1‑4 Alkylene or -CH2-Ph-, X is selected from any one of -OH, -SH, -SCH3, -COOH, -NH2, -NHCH3, -CONH2, -NHC(=NH)NH2, imidazolyl and indolyl. The isopalmitoyl amino acid compound of the present invention has strong water solubility, simple preparation, environmental friendliness and is suitable for industrial production. The present invention also relates to an amino acid surfactant, which has strong water solubility and low irritation. The present invention also relates to an application of an isopalmitoyl amino acid compound in the field of daily chemicals or the field of medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of surfactants and relates to an amino acid surfactant, in particular to an isopalmitoyl amino acid compound and a preparation method and application thereof. Background Art

[0002] Surfactants are widely used in daily chemical products. They have multiple functions such as emulsification, dispersion, solubilization, etc. and play an important role. Traditional surfactants, such as sodium lauryl polyoxyethylene ether sulfate (AES), have problems such as high irritation, high toxicity, difficult degradation and poor compatibility. Amino acid surfactants are a class of green surfactants based on amino acids. Compared with traditional surfactants, amino acid surfactants have the advantages of a wide source of biomass raw materials, low toxicity and side effects, mild performance, antibacterial, and biodegradability. Amino acid surfactants synthesized from amino acids such as sarcosine, aspartic acid and sodium methyl taurate as raw materials and fatty acids such as lauroyl acid, myristic acid and palmitic acid have been widely used in the field of daily chemicals. The main daily chemical products used are shampoo, shower gel, hand soap, facial cleanser and baby washing products.

[0003] With the development of social economy and the improvement of people's living standards, people have higher expectations for product quality, safety and environmental protection. The development of new surfactants has good economic and social effects.

[0004] Based on this, it is necessary to provide a new type of amino acid surfactant to meet market demand. Summary of the invention

[0005] The invention provides an isopalmitoyl amino acid compound, which has high water solubility and low irritation and can be used as a surfactant to solve some of the above problems.

[0006] The first aspect of the present invention provides an isopalmitoyl amino acid compound, the general structural formula of the isopalmitoyl amino acid compound is shown in formula (I):

[0007]

[0008] in,

[0009] Z 1 C 8 alkyl;

[0010] Z 2 C 6 alkyl;

[0011] R 1 is H, or an alkyl group;

[0012] R 2 H, C1-4 Alkyl, benzyl, -L 1 -X; where L 1 C 1-4 Alkylene or -CH 2 -Ph-, X is selected from -OH, -SH, -SCH 3 , -COOH, -NH 2 、-NHCH 3 、-CONH 2 、-NHC(=NH)NH 2 , imidazolyl and indolyl;

[0013] n is 0, 1 or 2;

[0014] M is lithium, sodium, potassium, calcium, magnesium, barium or ammonium.

[0015] In some embodiments of the present invention, in the isopalmitoyl amino acid compound,

[0016] Z 1 is n-octyl; and / or,

[0017] Z 2 is n-hexyl; and / or,

[0018] R 1 is H or methyl; and / or,

[0019] M is sodium or potassium.

[0020] In some embodiments of the present invention, in the isopalmitoyl amino acid compound, R 2 Select any one from the following groups:

[0021] (I) Group: H;

[0022] Group (II): -CH 3 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )CH 2 CH 3 and -CH 2 -Ph;

[0023] Group (III): -CH 2 OH, -CH(CH 3 )OH or

[0024] Group (IV): -CH 2 SH and -CH 2CH 2 SCH 3 ;

[0025] (V) Group: -CH 2 COOH and -CH 2 CH 2 COOH;

[0026] (Group VI): -CH 2 CH 2 CH 2 NH 2 、-CH 2 CH 2 CH 2 CH 2 NH 2 and -CH 2 NHCH 3 ;

[0027] Group (VII): -CH 2 CONH 2 , CH 2 CH 2 CONH 2 、-CH 2 CH 2 CH 2 NHC(=NH)NH 2 ,

[0028] Wherein, "*" represents the site connected to the backbone carbon in formula (I).

[0029] In some embodiments of the present invention, among the isopalmitoyl amino acid compounds, the isopalmitoyl amino acid compound is selected from any one of the following:

[0030]

[0031] In some embodiments of the present invention, among the isopalmitoyl amino acid compounds, the isopalmitoyl amino acid compound is selected from any one of the following:

[0032]

[0033] The second aspect of the present invention provides a method for preparing an isopalmitoyl amino acid compound, comprising the following steps:

[0034] isopalmitoyl chloride is prepared by subjecting isopalmitic acid to an acyl chlorination reaction with a chlorinating agent;

[0035] The amino acid compound, the acid binding agent and the solvent are mixed, and the isopalmitoyl chloride is added to carry out an amidation reaction to prepare an isopalmitoyl amino acid compound;

[0036] Wherein, the structure of the amino acid compound is NH 2 -CH(R 2 )-COOH, where R 2 is as defined in the first aspect of the present invention.

[0037] In some embodiments of the present invention, in the method for preparing the isopalmitoyl amino acid compound:

[0038] The molar ratio of the isopalmitoyl chloride to the amino acid compound is 1.0:(1.0-2.0); and / or,

[0039] The reaction temperature of the amidation reaction is 0 to 40° C.; and / or,

[0040] In the amidation reaction, the pH of the reaction solution is 8-12.

[0041] The third aspect of the present invention provides an isopalmitoyl amino acid compound, the general structural formula of the isopalmitoyl amino acid compound is shown in formula (II):

[0042]

[0043] Among them, Z 1 , Z 2 , R 1 , R 2 , n are defined as in the first aspect of the present invention.

[0044] The fourth aspect of the present invention provides an amino acid surfactant, which is the isopalmitoyl amino acid compound provided by the first aspect of the present invention, or the isopalmitoyl amino acid compound prepared by the preparation method provided by the second aspect of the present invention.

[0045] The fifth aspect of the present invention provides the use of the isopalmitoyl amino acid compounds provided in the first aspect of the present invention, or the isopalmitoyl amino acid compounds prepared by the preparation method provided in the second aspect of the present invention, or the isopalmitoyl amino acid compounds provided in the third aspect of the present invention in the field of daily chemicals or medicine.

[0046] The isopalmitoyl amino acid compound of the present invention has a suitable branched chain structure and has stronger water solubility than traditional fatty acyl amino acids, and can be used as a surfactant in the field of daily chemicals or medicine.

[0047] The isopalmitoyl amino acid surfactant of the invention has high water solubility and low irritation and has excellent application prospects.

[0048] The preparation process of the isopalmitoyl amino acid compound of the present invention is relatively simple and suitable for industrial large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0050] Figure 1 It is a scoring standard for the degree of blood vessel damage of the chick embryo chorioallantoic membrane in one embodiment of the present invention. The higher the score, the more severe the damage. 0 points indicate that the blood vessel is almost undamaged, and 8 points indicate that the blood vessel is severely damaged. DETAILED DESCRIPTION

[0051] Below in conjunction with specific embodiment and accompanying drawing, isopalmitoyl amino acid compounds of the present invention are described in further detail.The present invention can be realized in many different forms, is not limited to the embodiment described herein.On the contrary, the purpose of providing these embodiments is to make the disclosure of the present invention be understood more thoroughly and comprehensively.

[0052] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0053] the term

[0054] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0055] Herein, "amino acid" can be natural amino acid or non-natural amino acid, and can be L-type, D-type or L / D type. "Amino acid" used herein can be selected from the group consisting of, but not limited to, glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline, sarcosine, serine, threonine, cysteine, methionine, tyrosine, aspartic acid, glutamic acid, asparagine, glutamine, lysine, arginine, histidine, tryptophan, hydroxyproline, ornithine, etc.

[0056] Herein, unless otherwise defined, an amino group refers to -OH, and a carboxyl group refers to -COOH.

[0057] As used herein, the term "alkyl" refers to a monovalent residue formed by the loss of a hydrogen atom from a saturated hydrocarbon containing a primary (normal) carbon atom, a secondary carbon atom, a tertiary carbon atom, a quaternary carbon atom, or a combination thereof. 1 ~ 9 "Alkyl" refers to an alkyl group containing 1 to 9 carbon atoms, each occurrence of which can be independently C 1 Alkyl, C 2 Alkyl, C 3 Alkyl, C 4 Alkyl, C 5 Alkyl, C 6 Alkyl, C 7 Alkyl, C 8 Alkyl or C 9 Suitable examples include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH (CH 3 ) 2 ), 1-butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl (i-Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH (CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH 3 ) 3 ), 1-pentyl (n-pentyl, -CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methyl-2-butyl (-C(CH 3 )2 CH 2 CH 3 ), 3-methyl-2-butyl (-CH(CH 3 )CH(CH 3 ) 2 ), 3-methyl-1-butyl (-CH 2 CH 2 CH(CH 3 ) 2 ), 2-methyl-1-butyl (-CH 2 CH(CH 3 )CH 2 CH 3 )、1-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-hexyl (-CH(CH 3 )CH 2 CH 2 CH 2 CH 3 )、3-hexyl(-CH(CH 2 CH 3 )(CH 2 CH 2 CH 3 ))、2-methyl-2-pentyl (-C(CH 3 ) 2 CH 2 CH 2 CH 3 ), 3-methyl-2-pentyl (-CH(CH 3 )CH(CH 3 )CH 2 CH 3 ), 4-methyl-2-pentyl (-CH(CH 3 )CH 2 CH(CH 3 ) 2 ), 3-methyl-3-pentyl (-C(CH 3 )(CH 2 CH 3 ) 2 ), 2-methyl-3-pentyl (-CH(CH 2 CH 3 )CH(CH 3 ) 2 )、2,3-dimethyl-2-butyl (-C(CH 3 ) 2 CH(CH3 ) 2 )、3,3-dimethyl-2-butyl (-CH(CH 3 )C(CH 3 ) 3 and octyl (-(CH 2 ) 7 CH 3 ).

[0058] As used herein, aryl, aromatic group, aromatic radical, aromatic and aromatic ring system have the same meaning and are interchangeable.

[0059] Herein, the term "aryl" refers to an aromatic hydrocarbon group derived from an aromatic ring compound by removing a hydrogen atom, which may be a monocyclic aromatic group, a condensed aromatic group, or a polycyclic aromatic group. For polycyclic rings, at least one is an aromatic ring system. For example, "C 5 ~C 10 "Aryl" refers to an aromatic group containing 5 to 10 carbon atoms, each occurrence of which can be independently C 5 Aryl, C 6 Aryl, C 7 Aryl, C 8 Aryl, C 9 Aryl or C 10 Suitable examples include, but are not limited to, benzene, biphenyl, naphthalene, anthracene, phenanthrene, perylene, triphenylene, and derivatives thereof.

[0060] Herein, the term "heterocyclic group" means that at least one carbon atom on the basis of a cycloalkyl group is replaced by a non-carbon atom, which may be a N atom, an O atom, an S atom, etc., and may be a saturated ring or a partially unsaturated ring. Phrases containing this term, such as "C 4 ~C 9 "Heterocyclic group" refers to a heterocyclic group containing 4 to 9 carbon atoms, each occurrence of which can be independently C 4 Heteroalkyl, C 5 Heteroalkyl, C 6 Heteroalkyl, C 7 Heteroalkyl, C 8 Heteroalkyl or C 9 Suitable examples include, but are not limited to, dihydropyridinyl, tetrahydropyridinyl (piperidinyl), tetrahydrothiophenyl, thio-oxidized tetrahydrothiophenyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl.

[0061] As used herein, the term "polyol" refers to an alcohol compound containing two or more hydroxyl groups (-OH) in the molecule.

[0062] Herein, unless otherwise specified, -COOM means -C(=O)OM.

[0063] The terms "and / or", "or / and", and "and / or" used in this article include any one of two or more related listed items, and also include any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").

[0064] Herein, “preferred”, “better”, “better”, etc. are only used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute limitations on the scope of protection of the present invention.

[0065] In the present invention, “further”, “furthermore”, “particularly”, etc. are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present invention.

[0066] In the present invention, in the "first aspect", "second aspect", "third aspect", "fourth aspect", "fifth aspect", etc., the terms "first", "second", "third", "fourth", "fifth", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", "fifth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.

[0067] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0068] In the present invention, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges included therein.

[0069] The temperature parameters in the present invention, if not specifically limited, are allowed to be either constant temperature treatment or to vary within a certain temperature range. It should be understood that the constant temperature treatment allows the temperature to fluctuate within the precision range controlled by the instrument. Fluctuations within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are allowed.

[0070] In the present invention, "room temperature" means that no temperature control operation is applied, mainly refers to 4°C to 35°C, preferably refers to 4°C to 30°C, and more preferably, for example, 20°C ± 0.5°C, 20°C ± 1°C, 20°C ± 2°C, 20°C ± 3°C, 20°C ± 4°C, 20°C ± 5°C, 20°C to 30°C, etc. Examples of "room temperature" in the present invention include 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, etc.

[0071] In the first aspect of the present invention, an isopalmitoyl amino acid compound is provided, and the general structural formula of the isopalmitoyl amino acid compound is shown in formula (I):

[0072]

[0073] in,

[0074] Z 1 C 8 alkyl;

[0075] Z 2 C 6 alkyl;

[0076] R 1 is H, or an alkyl group;

[0077] R 2 H, C 1-4 Alkyl, benzyl, -L1 -X; where L 1 C 1-4 Alkylene or -CH 2 -Ph-, X is selected from -OH, -SH, -SCH 3 , -COOH, -NH 2 、-NHCH 3 、-CONH 2 、-NHC(=NH)NH 2 , imidazolyl and indolyl;

[0078] n is 0, 1 or 2;

[0079] M is lithium, sodium, potassium, calcium, magnesium, barium or ammonium.

[0080] In some embodiments, Z in formula (I) 1 C 8 Alkyl, further, C 8 The alkyl group may be an open chain or contain a cyclic structure. In some embodiments, Z in formula (I) 1 C 8 Alkyl, C 8 The alkyl group is an open-chain structure. In some embodiments, Z in formula (I) 1 C 8 Alkyl, C 8 The alkyl group contains a ring structure.

[0081] In some embodiments, Z in formula (I) 1 C 8 Alkyl, further, C 8 The alkyl group may be a straight chain or a branched chain. 1 C 8 Alkyl, C 8 The alkyl group is a straight chain structure. In some embodiments, Z in formula (I) 1 C 8 Alkyl, C 8 The alkyl group is a branched structure.

[0082] In some embodiments, Z in formula (I) 1 It is n-octyl.

[0083] In some embodiments, Z in formula (I) 2 C 6 Alkyl, further, C 6 The alkyl group may be an open chain or contain a cyclic structure. In some embodiments, Z in formula (I) 1 C 6 Alkyl, C 6The alkyl group is an open-chain structure. In some embodiments, Z in formula (I) 1 C 6 Alkyl, C 6 The alkyl group contains a ring structure.

[0084] In some embodiments, Z in formula (I) 1 C 6 Alkyl, further, C 6 The alkyl group may be a straight chain or a branched chain. 1 C 6 Alkyl, C 6 The alkyl group is a straight chain structure. In some embodiments, Z in formula (I) 1 C 6 Alkyl, C 6 The alkyl group is a branched structure.

[0085] In some embodiments, Z in formula (I) 2 It is n-hexyl.

[0086] In some embodiments, R in formula (I) 1 It can be selected from any one of the following groups: H, a straight-chain alkyl group having 1 to 10 C atoms, a branched-chain alkyl group having 3 to 10 C atoms, a cyclic alkyl group having 3 to 10 C atoms, -CN, nitro, -CF 3 , -Cl, -Br, -F, -I, phenyl, biphenyl, naphthyl, etc.

[0087] In some embodiments, R in formula (I) 1 H or C 1-20 Alkyl, which may further be H or C 1-10 Alkyl, which may further be H or C 1-6 Alkyl, which may further be H or C 1-3 The alkyl group may further be H or methyl.

[0088] In some embodiments, R in formula (I) 1 In some embodiments, R in formula (I) 1 is H. In some embodiments, R in formula (I) 1 It is methyl.

[0089] In some embodiments, R in formula (I) 2 Can be H, C 1-4 Alkyl, benzyl, -L 1 -X; where L 1 C 1-4 Alkylene or -CH 2 -Ph-, X is selected from -OH, -SH, -SCH3 , -COOH, -NH 2 、-NHCH 3 、-CONH 2 、-NHC(=NH)NH 2 , imidazolyl and indolyl.

[0090] In some embodiments, R in formula (I) 2 Can be selected from any of the following groups:

[0091] (I) Group: H;

[0092] Group (II): -CH 3 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )CH 2 CH 3 and -CH 2 -Ph;

[0093] Group (III): -CH 2 OH, -CH(CH 3 )OH or

[0094] Group (IV): -CH 2 SH and -CH 2 CH 2 SCH 3 ;

[0095] (V) Group: -CH 2 COOH and -CH 2 CH 2 COOH;

[0096] (Group VI): -CH 2 CH 2 CH 2 NH 2 、-CH 2 CH 2 CH 2 CH 2 NH 2 and -CH 2 NHCH 3 ;

[0097] Group (VII): -CH 2 CONH 2 , CH 2 CH 2 CONH2 、-CH 2 CH 2 CH 2 NHC(=NH)NH 2 ,

[0098] In some embodiments, R in formula (I) 2 Can be selected from H, -COOH or CH 3 In some embodiments, R in formula (I) 2 is H. In some embodiments, R in formula (I) 2 In some embodiments, R in formula (I) 2 CH 3 .

[0099] In some embodiments, n in formula (I) can be 0 or 1 or 2.

[0100] In some embodiments, n in formula (I) can be 1 or 2.

[0101] In some embodiments, M in formula (I) can be lithium, sodium, potassium, calcium, magnesium, barium or ammonium.

[0102] In some embodiments, M in formula (I) can be sodium or potassium.

[0103] In some embodiments, the isopalmitoyl amino acid compound can be selected from any of the following:

[0104]

[0105] In some embodiments, in formula (I) Select from any of the following groups:

[0106] In some embodiments, in formula (I) Select from any of the following groups:

[0107] In some embodiments, in formula (I) Select from any of the following groups:

[0108] In some embodiments, the isopalmitoyl amino acid compound can be selected from any of the following:

[0109]

[0110] The present invention also provides an isopalmitoyl amino acid compound having a general structural formula as shown in formula (II):

[0111]

[0112] Among them, Z 1 , Z 2 , R 1 , R 2 , n are defined as in formula (I).

[0113] In some embodiments, the isopalmitoyl amino acid compound is selected from any one of the following:

[0114]

[0115] The second aspect of the present invention provides a method for preparing isopalmitoyl amino acid compounds, the raw materials are easily available, and the operation is simple: isopalmitoyl chloride and amino acid are used as raw materials, an amidation reaction is carried out in the presence of an acid binding agent, and depending on the substrate, the amidation reaction is carried out under appropriate temperature conditions (such as 20° C. to 30° C.) to obtain the corresponding isopalmitoyl amino acid acid compounds. The post-processing of the reaction is simple, the solvent can be recycled, and it is green and environmentally friendly.

[0116] The reaction mechanism is shown below:

[0117]

[0118] Among them, Z 1 , Z 2 , R 1 , R 2 , M, n, as defined in the first aspect of the present invention.

[0119] In some embodiments, the reaction mechanism is shown below:

[0120]

[0121] Among them, R 1 , R 2 , M, n, as defined in the first aspect of the present invention; in some preferred embodiments, C 8 H 17 Refers to n-octyl, C 6 H 13 Refers to the correct self.

[0122] In a second aspect of the present invention, a method for preparing an isopalmitoyl amino acid compound is provided, comprising the following steps:

[0123] S100: isopalmitoyl chloride is prepared by adding a chlorinating agent to isopalmitoyl chloride to isopalmitoyl chloride.

[0124] S200: mixing an amino acid compound, an acid-binding agent and a solvent, adding the isopalmitoyl chloride to carry out an amidation reaction to prepare an isopalmitoyl amino acid compound; wherein the structure of the amino acid compound is NH 2 -CH(R 2 )-COOH, where R 2 As defined in the first aspect of the present invention.

[0125] S100: Preparation of isopalmitoyl chloride

[0126] Isopalmitoyl chloride can be prepared by the following preparation steps: adding isopalmitic acid and n-heptane to mix, and dropping a chlorination reagent into a reaction bottle under stirring conditions; after the dropwise addition is completed, reacting at room temperature until the isopalmitic acid reacts completely (cannot be detected by thin layer chromatography TLC); concentrating the reaction solution to obtain isopalmitoyl chloride.

[0127] In some embodiments of the present invention, the molar ratio of isopalmitic acid to the chlorination agent is (0.6-1):1, and can further be (0.6-0.8):1, and the molar ratios are 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, etc. In some embodiments, the molar ratio of isopalmitic acid to the chlorination agent is 0.39:0.507.

[0128] In some embodiments of the present invention, the chlorination agent is selected from any one of oxalyl chloride, thionyl chloride, phosgene and phosphorus trichloride. In some embodiments, the chlorination agent is oxalyl chloride.

[0129] In some embodiments of the present invention, in the acyl chloride reaction, the dropwise addition temperature of the chlorination reagent is 0°C to 15°C, and can further be 0°C to 10°C. The reaction temperature can be selected from 0°C to 10°C, 0°C to 8°C, 0°C to 5°C, 0°C to 4°C, 3°C to 8°C, 5°C to 10°C, etc. In the present invention, in the acyl chloride reaction, the dropwise addition time of the chlorination reagent is not particularly limited, and it is preferable to maintain the internal temperature of the reaction solution at 0°C to 10°C. In some embodiments, the dropwise addition time of the chlorination reagent is 3h to 4h.

[0130] In some embodiments of the present invention, the reaction temperature of the chlorination reaction is room temperature, and can further be 20° C. to 30° C. In the present invention, the chlorination reaction time is not particularly limited, and it is preferred that the raw materials are completely reacted. In some embodiments, the chlorination reaction time is 3h to 4h.

[0131] When the raw material fatty acid (isopalmitic acid), the chlorination agent and their molar ratio are determined, the method of preparing the fatty acid and the chlorination agent into an acyl chloride is well known to those skilled in the art, and reference may also be made to the preparation methods reported in the literature (CN105126698A, CN109482100A). No further description will be given here.

[0132] S200: Preparation of isopalmitoyl amino acid compounds

[0133] The isopalmitoyl amino acid compound can be prepared by a method including the following preparation steps: mixing an amino acid compound, an acid binding agent and a solvent, adding the isopalmitoyl chloride to carry out an amidation reaction, and preparing the isopalmitoyl amino acid compound.

[0134] In some embodiments of the present invention, the amino acid compound is selected from aspartic acid, sarcosine or methylalanine.

[0135] In some embodiments of the present invention, the acid binding agent is selected from any one of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and triethanolamine. In some embodiments, the acid binding agent is selected from sodium hydroxide or potassium hydroxide.

[0136] In some embodiments of the present invention, the solvent is selected from water, or a mixture of water and an organic solvent. In certain embodiments, the solvent is water, and in certain embodiments, the solvent is a mixture of water and an organic solvent. In certain embodiments, the solvent is water, and a mixture of any one of acetone, ethanol or a polyol.

[0137] In some embodiments of the present invention, the solvent is a mixture of water and an organic solvent. In some embodiments, the amino acid compound is mixed with an acid binding agent and water, and then an organic solvent is added to mix. In some embodiments, the solvent is a mixture of water and acetone. In some embodiments, the amino acid compound is mixed with an acid binding agent and water, and then acetone is added to mix.

[0138] In some embodiments of the present invention, the molar ratio of the amino acid compound to the acid binding agent is (1.1-1.5):1, and can further be (1.1-1.2):1, and the molar ratios are 1.5:1, 1.4:1, 1.3:1, 1.2:1, 1.1:1, 1:1, etc. In some embodiments, the molar ratio of the amino acid compound to the acid binding agent is 1:1.

[0139] In some embodiments of the present invention, the molar ratio of isopalmitoyl chloride to the amino acid compound is 1.0:(1.0-2.0), and can further be 1.0:(1.1-1.5), and the molar ratios are 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, etc. In some embodiments, the molar ratio of isopalmitoyl chloride to the amino acid compound is 0.073:0.109, 0.073:0.102, 0.073:0.087.

[0140] In some embodiments of the present invention, the reaction temperature for the amidation reaction is 0°C to 40°C, and can further be 10°C to 30°C. Examples of reaction temperatures include 10°C, 11°C, 13°C, 15°C, 18°C, 20°C, 22°C, 25°C, 27°C, 28°C, 30°C, etc. In some embodiments, the reaction temperature for the amidation reaction can be selected from 15°C to 25°C, 20°C to 30°C, 10°C to 20°C, 10°C to 15°C, 20°C to 25°C, etc.

[0141] In some embodiments of the present invention, the pH value of the reaction environment (solution environment) for the amidation reaction is 8 to 12, and more preferably 9 to 11. When the pH is lower than 9, the reaction rate is slow, and when the pH is higher than 11, hydrolysis is likely to occur, producing byproducts such as isopalmitic acid. In some embodiments, the pH value for the amidation reaction is selected from 8 to 12, 9 to 11, 8 to 9, 8 to 10, 9 to 10, 10 to 11, and the like.

[0142] In the present invention, the duration of the amidation reaction is not particularly limited, and it is preferred that the raw materials are completely reacted. In some embodiments, the amidation reaction is 2 to 3 hours.

[0143] The fourth aspect of the present invention provides an amino acid surfactant, which is the isopalmitoyl amino acid compound provided by the first aspect of the present invention, or the isopalmitoyl amino acid compound prepared by the preparation method provided by the second aspect of the present invention. The isopalmitoyl amino acid compound of the present invention has a suitable branched structure and has stronger water solubility than traditional fatty acyl amino acids, and can be used as a surfactant in the field of daily chemicals or medicine.

[0144] The fifth aspect of the present invention provides the isopalmitoyl amino acid compounds provided in the first aspect of the present invention, or the isopalmitoyl amino acid compounds prepared by the preparation method provided in the second aspect of the present invention, or the use of the isopalmitoyl amino acid compounds provided in the third aspect of the present invention.

[0145] In some embodiments, the application is in the field of daily chemicals or medicine.

[0146] In some embodiments, the application is application as a surfactant in the field of daily chemicals or medicine.

[0147] When the isopalmitoyl amino acid compounds provided by the present invention are used as surfactants, in addition to having the advantages of common amino acid surfactants such as wide raw material sources, small toxic and side effects, mild performance, antibacterial, and biodegradability, they also have the characteristics of high water solubility and low irritation, and can be applied to products in the field of daily chemicals and the field of medicine.

[0148] In some embodiments of the present invention, the isopalmitoyl amino acid compounds of the present invention can reduce the damage to the chorioallantoic membrane vascular system of fertilized chicken embryos.

[0149] The following are some specific embodiments.

[0150] For experimental parameters not specified in the following specific embodiments, reference is made to the instructions given in the present application document, and reference may also be made to experimental manuals in the art or other experimental methods known in the art, or to experimental conditions recommended by manufacturers.

[0151] The raw materials and reagents involved in the following specific examples can be obtained from commercial sources, or can be prepared by those skilled in the art according to known methods.

[0152] Example 1

[0153] 1.1 Preparation of isopalmitoyl chloride

[0154] Add isopalmitic acid (0.39 mol, 100 g) and n-heptane (150 mL) to a 500 mL reaction flask and mix. Under stirring, cool to 0°C-10°C, add oxalyl chloride (64.4 g, 0.507 mol) dropwise to the reaction flask, and maintain the reaction temperature at 0°C-10°C during the addition. After about 3-4 hours of completion of the addition, heat to 20°C-30°C, and continue the reaction for 1-2 hours until the conversion of isopalmitic acid is complete. Concentrate the reaction solution under reduced pressure at below 55°C until no solvent is distilled off to obtain isopalmitoyl chloride (0.383 mol, 105.2 g), a light yellow liquid with a yield of 98% and a purity of 97%.

[0155] 1.2 Preparation of isopalmitoyl aspartic acid

[0156] Aspartic acid (0.109 mol, 14.5 g) and water (80 mL) were added to a 250 mL reaction flask and mixed. Sodium hydroxide (0.109 mol, 4.4 g) was added under stirring to prepare a sodium aspartate aqueous solution. Acetone (40 mL) was added and mixed. Isopalmitoyl chloride (0.073 mol, 20 g) and a 32% sodium hydroxide aqueous solution (0.146 mol, 18.3 g) were added dropwise to the reaction flask. During the addition, the pH of the reaction solution was maintained at 10-11 and the reaction temperature was maintained at 10°C-20°C. The addition was completed in about 2-3 hours. After the addition was completed, the reaction was continued for 1-2 hours with insulation until the conversion of the raw material isopalmitoyl chloride was completed. Hydrochloric acid was added to adjust the pH to 3-4, the acetone was concentrated and recovered, filtered, washed, and dried to obtain isopalmitoyl aspartic acid (0.067 mol, 24.9 g, yield 92%) as a white solid powder: ESI-MS (m / z): 370.3. 1 HNMR (CDCl 3)δ(ppm):0.86-0.89(m, 6H),1.12-1.35(m, 20H),1.36-1.50(m,2H),1.51-1.66(m,2H),2.06-2.16(m,1H),2.85-3.15(d,2H),4.87-4.99(m,1H),6.56-6.68(d,1H).

[0157] 1.3 Preparation of Sodium Isopalmitoyl Aspartate

[0158] The isopalmitoyl aspartic acid (0.054 mol, 20 g) prepared in step 1.2 was added to a solution prepared by sodium hydroxide (0.108 mol, 4.3 g) and water (100 mL), stirred to dissolve, and dried to remove water to obtain sodium isopalmitoyl aspartate (0.054 mol, 22.5 g) as a white solid powder.

[0159] Example 2

[0160] 2.1 Preparation of isopalmitoyl chloride

[0161] Isopalmitoyl chloride was prepared by the same preparation method as step 1.1 in Example 1.

[0162] 2.2 Preparation of isopalmitoyl sarcosine

[0163] Sarcosine (0.102 mol, 9.1 g) and water (80 mL) were added to a 250 mL reaction flask and mixed. Sodium hydroxide (0.102 mol, 4.1 g) was added under stirring to prepare a sodium sarcosinate aqueous solution. Acetone (40 mL) was added and mixed. Isopalmitoyl chloride (0.073 mol, 20 g) and a 32% sodium hydroxide aqueous solution (0.146 mol, 18.3 g) were added dropwise to the reaction flask. During the addition, the pH of the reaction solution was maintained at 10 to 11 and the reaction temperature was maintained at 10° C. to 20° C. The addition was completed in about 2 to 3 hours. After the addition was completed, the reaction was continued for 1 to 2 hours with insulation until the conversion of the raw material isopalmitoyl chloride was completed. Hydrochloric acid was added to adjust the pH to 3 to 4, the acetone was concentrated and recovered, the stratification was allowed to stand, and the organic layer was dried to obtain isopalmitoyl sarcosine (0.066 mol, 21.5 g, yield 90%) as a light yellow oil: ESI-MS (m / z): 326.3. 1 HNMR (CDCl 3 )δ0.86-0.89(m, 6H), 1.17-1.33(m, 20H), 1.41-1.47(m, 2H), 1.60-1.66(m, 2H), 2.67-2.71(m, 1H), 3.14(s, 3H), 4.15(s, 2H).

[0164] 2.3 Preparation of Sodium Isopalmitoyl Sarcosinate

[0165] The isopalmitoyl sarcosine (0.046 mol, 15 g) obtained in step 2.2 was added to a solution prepared by sodium hydroxide (0.046 mol, 1.8 g) and water (100 mL), stirred to dissolve, and dried to remove water to obtain sodium isopalmitoyl sarcosine (0.046 mol, 16.1 g) as an off-white solid powder.

[0166] Example 3

[0167] 3.1 Preparation of isopalmitoyl chloride

[0168] Isopalmitoyl chloride was prepared by the same preparation method as step 1.1 in Example 1.

[0169] 3.2 Preparation of isopalmitoyl methyl alanine

[0170] Sodium methylalanine (0.109 mol, 13.7 g) and water (80 mL) were added to a 250 mL reaction flask, mixed, stirred and dissolved to obtain a sodium methylalanine aqueous solution; isopalmitoyl chloride (0.073 mol, 20 g) and 32% sodium hydroxide aqueous solution (0.146 mol, 18.3 g) were simultaneously added dropwise to the reaction flask. During the addition, the pH of the reaction solution was maintained at 9 to 10 and the reaction temperature was maintained at 15° C. to 25° C. The addition was completed in about 2 to 3 hours; after the addition was completed, the reaction was continued for 1 to 2 hours while keeping warm until the raw material isopalmitoyl chloride was completely converted; hydrochloric acid was added to adjust the pH to 3 to 4, the mixture was allowed to stand for stratification, and the organic layer was dried to obtain isopalmitoyl alanine (0.067 mol, 23.6 g, yield 92%) as a light yellow oil: ESI-MS (m / z): 340.3; 1 HNMR (CDCl 3 )δ0.85-0.88(m, 6H), 1.15-1.35(m, 20H), 1.37-1.42(m, 2H), 1.56-1.62(m, 2H), 2.57-2.62(m, 1H), 2.63-2.67(t, 2H), 3.10(s, 3H), 3.64-3.67(t, 2H).

[0171] 3.3 Preparation of potassium isopalmitoyl methylalanine

[0172] The isopalmitoylmethylalanine (0.043 mol, 15 g) prepared in step 4.2 was added to a solution prepared by potassium hydroxide (0.043 mol, 2.4 g) and water (100 mL), stirred to dissolve, and dried to remove water to obtain potassium isopalmitoylmethylalanine (0.043 mol, 16.3 g) as an off-white solid powder.

[0173] Comparative Example 1

[0174] Sodium palmitoyl aspartate was prepared by a preparation method substantially the same as that in Example 1, except that palmitic acid was used to prepare palmitic acid chloride for later use in step 1.1; the remaining parameters, including the type of raw materials, the amount used, and the preparation method, were the same as those in Example 1.

[0175] Comparative Example 2

[0176] Sodium palmitoyl sarcosinate was prepared by a preparation method substantially the same as that in Example 2, except that palmitic acid was used to prepare palmitic acid chloride for later use in step 1.1; the remaining parameters, including the type of raw materials, the amount used, and the preparation method, were the same as those in Example 2.

[0177] Comparative Example 3

[0178] Potassium palmitoyl methylalaninate was prepared by a preparation method substantially the same as that in Example 3, except that palmitic acid was used to prepare palmitic acid chloride in step 1.1 for later use; the remaining parameters, including the type of raw materials, the amount used, and the preparation method, were the same as those in Example 3.

[0179] Example 4 Performance Test

[0180] 4.1 Water solubility test

[0181] At room temperature, 10 g of water was used to test the maximum solubility of sodium isopalmitoyl aspartate (prepared in Example 1), sodium isopalmitoyl sarcosinate (prepared in Example 2), potassium isopalmitoyl methylalaninate (prepared in Example 3), sodium palmitoyl aspartate (prepared in Comparative Example 1), sodium palmitoyl sarcosinate (prepared in Comparative Example 2) and potassium palmitoyl methylalaninate (prepared in Comparative Example 3). The test results are shown in Table 1.

[0182] 4.2 Irritation test

[0183] Weigh sodium isopalmitoyl aspartate (prepared in Example 1), sodium isopalmitoyl sarcosinate (prepared in Example 2), potassium isopalmitoyl methylalaninate (prepared in Example 3), sodium palmitoyl aspartate (prepared in Comparative Example 1), sodium palmitoyl sarcosinate (prepared in Comparative Example 2), and potassium palmitoyl methylalaninate (prepared in Comparative Example 3), and prepare aqueous solutions with a mass percentage concentration of 10% for later use;

[0184] Fertilized chicken embryos incubated for 10 days were used as experimental samples. Taking advantage of the complete, obvious and transparent vascular system of the chorioallantoic membrane of fertilized chicken embryos, 0.5 mL of the above aqueous solution was directly contacted with the chorioallantoic membrane of 6 chicken embryos. After 3 minutes, the degree of damage to the chorioallantoic membrane blood vessels was observed, and the degree of damage such as coagulation, bleeding or dissolution of the blood vessels was scored. The scoring criteria are as follows: Figure 1 , Figure 1From 0 to 8 points, the coagulation, bleeding or dissolution of the chicken embryo blood vessels gradually worsened; among them, in the example picture with a score of 0, the blood vessel morphology was intact and no bleeding spots were seen, in the example picture with a score of 4, the blood vessels were dissolved and the bleeding spots were not obvious, and in the example picture with a score of 8, obvious punctate bleeding was seen. The score is the average of the vascular injury scores of the 6 chicken embryos. The scoring results are shown in Table 1.

[0185] Table 1 Water solubility and irritation test of surfactants in Examples 1 to 3 and Comparative Examples 1 to 3

[0186] Test items Example 1 Example 2 Example 3 Comparative Example 1 Comparative Example 2 Comparative Example 3 Water solubility (g / 10g) 3.6 2.5 3.0 2.6 1.3 1.8 Irritation rating 3.5 3.2 3.3 5.7 5.3 5.8

[0187] According to the performance test results in Table 1, under the same molecular weight, compared with traditional amino acid surfactants, the isopalmitoyl amino acid surfactant of the present invention has high solubility and low irritation, and has better comprehensive performance and wider application prospects.

[0188] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as a reference separately. Unless they conflict with the invention purpose and / or technical solution of the present application, the cited documents involved in the present invention are cited with all contents and all purposes. When the present invention involves cited documents, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the present invention involves cited documents, the examples and preferred embodiments of the cited relevant technical features may also be incorporated into this application as references, but are limited to the ability to implement the present invention. It should be understood that when the content of the citation conflicts with the description in this application, the present application shall prevail or be modified adaptively according to the description of this application.

[0189] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0190] The above-described embodiments only express several implementation methods of the present invention, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for those of ordinary skill in the art, without departing from the concept of the present invention, several variations and improvements can be made, which all belong to the protection scope of the present invention. In addition, it should be understood that after reading the above-mentioned teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and the equivalent forms obtained also fall within the protection scope of the present invention. It should also be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided by the present invention are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims, and the description and drawings may be used to explain the contents of the claims.

Claims

1. An isopalmitoyl amino acid compound, characterized in that The isopalmitoyl amino acid compound is selected from any one of the following: ; Z1 is n-octyl; Z2 is n-hexyl; for ; for ; M is lithium, sodium, potassium, calcium, magnesium, barium or ammonium.

2. The isopalmitoyl amino acid compound according to claim 1, wherein M is sodium or potassium.

3. The isopalmitoyl amino acid compound according to claim 1, wherein The isopalmitoyl amino acid compound is selected from any one of the following: 、 。 4. The method for preparing the isopalmitoyl amino acid compound according to any one of claims 1 to 3, characterized in that: The steps include: isopalmitoyl chloride is prepared by subjecting isopalmitic acid to an acyl chlorination reaction with a chlorinating agent; The amino acid compound, the acid binding agent and the solvent are mixed, and the isopalmitoyl chloride is added to carry out an amidation reaction to prepare an isopalmitoyl amino acid compound; Wherein, the amino acid compound is aspartic acid or methylalanine.

5. The method for preparing isopalmitoyl amino acid compounds according to claim 4, wherein: The molar ratio of the isopalmitoyl chloride to the amino acid compound is 1.0:(1.0-2.0); and / or, The reaction temperature of the amidation reaction is 0-40°C; and / or, In the amidation reaction, the pH of the reaction solution is 8-12.

6. An isopalmitoyl amino acid compound, characterized in that: The isopalmitoyl amino acid compound is selected from any one of the following: 、 。 7. An amino acid surfactant, characterized in that The amino acid surfactant is the isopalmitoyl amino acid compound according to any one of claims 1 to 3.

8. Use of the isopalmitoyl amino acid compound according to any one of claims 1 to 3 or the isopalmitoyl amino acid compound according to claim 6 as a surfactant in the field of daily chemicals.